GHRP-6 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: three subcutaneous injections daily, spaced at least 4 hours apart, typically morning, midday, and bedtime. GHRP-6 has a short half-life of approximately 2.5 hours, so splitting the daily amount across three doses sustains GH elevation far better than a single daily injection. Each injection is administered on an empty stomach, roughly 2 to 3 hours after a meal and about 30 minutes before eating, because circulating glucose and fatty acids blunt the GH response. At 5 mg/mL a 100 mcg dose is 2 units, 200 mcg is 4 units, and 300 mcg is 6 units on a U-100 insulin syringe, so every dose in this protocol is a small draw and none of them require splitting into a second injection. Sites are rotated systematically across abdomen, thighs, and upper arms.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: 100 mcg per injection, three times daily. The opening titration step gauges tolerance, since appetite stimulation and flushing are most noticeable when dosing starts.
• Weeks 3 to 4: 200 mcg per injection. GH pulse amplitude rises and IGF-1 begins to climb.
• Weeks 5 to 12: 300 mcg per injection, the maintenance dose, where body composition and recovery changes accumulate.
• End of cycle: the reference course runs 8 to 12 weeks, after which dosing stops rather than continuing indefinitely.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Use within 7 days of reconstitution for optimal potency.
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe, so 100 mcg = 2 units, 200 mcg = 4 units, and 300 mcg = 6 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions, with desiccant if available.
• Reconstituted: refrigerate at 2 to 8 °C and use within 7 days.

• Avoid freeze-thaw cycles: do not refreeze reconstituted solution, and prepare aliquots if longer storage is needed.
• Allow vials to reach room temperature before opening to minimize condensation.

Supplies Needed

Planning below is based on the full 12 week course with three injections daily and gradual titration, which reaches 900 mcg per day, or 6.3 mg per week, at the 300 mcg maintenance dose.

Peptide Vials (GHRP-6, 5 mg vial):

• The titration schedule uses about 63 mg of GHRP-6 over 12 weeks (4.2 mg in weeks 1 to 2, 8.4 mg in weeks 3 to 4, and 50.4 mg in weeks 5 to 12), which is about 13 vials of 5 mg.

Insulin Syringes (U-100):

• Per week: 21 U-100 insulin syringes, at 3 injections per day across 7 days.
• Full 12 week cycle: 252 syringes, which is 3 boxes of 100.

Bacteriostatic Water (10 mL bottles):

• Each 5 mg vial takes 1.0 mL of bacteriostatic water, so a single 10 mL bottle covers 10 vials and the 13 vial cycle needs 2 bottles.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 42 per week at three injections daily.
• Full 12 week cycle: 504 swabs, which is 6 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for every injection and dispose of it in a sharps container. Rotate injection sites systematically across abdomen, thighs, and upper arms to reduce lipohypertrophy and local irritation, and inject slowly, waiting a few seconds before withdrawing the needle.
• GHRP-6 is the most appetite-stimulating of the GHRP family because it is a direct ghrelin mimetic. Marked hunger within 20 to 30 minutes of a dose is expected rather than unusual, which suits a surplus but works against a deficit.
• At 5 mg/mL a vial holds 5 mg in 1.0 mL, so at the 900 mcg daily maintenance total one vial covers about five and a half days and falls inside the 7 day post-reconstitution window. During the lower titration weeks a vial will not be finished inside 7 days, so the remainder is discarded rather than carried over, which is why the vial count is higher than raw milligram usage alone suggests.
• Empty stomach dosing matters. Food, particularly carbohydrate and fat, blunts the GH pulse, so injections are placed 2 to 3 hours after a meal and about 30 minutes before the next one.
• Document daily doses, timing, and sites to keep the three-times-daily cadence consistent across the cycle, since compliance drives the IGF-1 response more than dose size does.
• Regulatory Note: GHRP-6 has no approved therapeutic indication in any jurisdiction and is not an approved medicine. It is supplied for research use only and not for human consumption.

How This Works

GHRP-6 acts as a synthetic ghrelin mimetic, binding the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and hypothalamus. That activation triggers acute pulsatile GH release from somatotroph cells while simultaneously lifting somatostatin's inhibitory brake on secretion, producing a sharper pulse than either mechanism alone. Unlike continuous exogenous GH administration, GHRP-6 leaves physiological feedback intact: as GH and IGF-1 rise, endogenous somatostatin increases and prevents runaway elevation, keeping pulses inside normal physiologic ranges. Beyond the endocrine pathway, GHRP-6 also engages the CD36 receptor on immune and muscle cells, activating cell-survival signaling cascades such as PI3K/Akt that protect tissue from oxidative stress and inflammation. That second pathway accounts for the cytoprotective findings reported in preclinical models, including cardioprotection, neuroprotection, and anti-fibrotic effects such as reduced hypertrophic scarring.

Benefits & Side Effects

Observations from the published record.

• Muscle growth and fat loss: elevated GH and IGF-1 support increased lean body mass and reduced fat mass over the course of a cycle.
• Enhanced recovery: improved sleep architecture with increased slow-wave sleep, plus faster tissue repair.
• Tissue protection and connective tissue support: preclinical work shows cytoprotective effects including reduced scar formation, cardioprotection, and neuroprotection, and elevated IGF-1 may support collagen synthesis and connective tissue repair.
• Appetite stimulation: hunger increases through ghrelin receptor activation, which is useful for weight gain goals and a problem for anyone in a deficit.
• Side effects: transient mild increases in cortisol and ACTH that are typically not clinically significant, water retention, occasional injection site reactions such as redness, itching, and mild swelling, and possible transient dizziness or flushing immediately after a dose from the rapid GH spike.
• Overall tolerability: generally well-tolerated in human trials at research doses, with no major safety concerns reported.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: adequate protein at 1.6 to 2.2 g/kg body weight supports the anabolic processes elevated GH drives, and carbohydrate and fat intake is timed away from injections so it does not blunt the GH release.
• Training: resistance training combined with moderate cardiovascular activity puts the elevated GH and IGF-1 to work rather than leaving it unused.
• Sleep: 7 to 9 hours of quality sleep, since the largest natural GH pulses occur during deep sleep and GHRP-6's effect on sleep architecture compounds with it.
• Hydration and stress management: proper hydration supports metabolic processes and limits water retention, while chronic stress raises cortisol and interferes with GH secretion.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Growth hormone-releasing peptides: comprehensive review of GHRP mechanisms (European Journal of Endocrinology, 1997).
2. Synthetic GHRPs: historical appraisal of cytoprotective effects and mechanisms (Clinical Medicine Insights: Cardiology, 2017).
3. Pharmacokinetic study of GHRP-6 in healthy male volunteers (European Journal of Pharmaceutical Sciences, 2013).
4. GHRP-6 prevents cutaneous hypertrophic scarring: proteome study (International Wound Journal, 2018).